Literature DB >> 12730539

Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.

N J McHugh1, C Balachrishnan, S M Jones.   

Abstract

OBJECTIVE: To assess the evolution of disease subgroups and the frequency of progression of peripheral joint disease in a prospectively studied cohort of patients with psoriatic arthritis (PsA).
METHODS: The cohort was identified as the first consecutive 100 patients attending a psoriatic arthritis clinic and who had been the subject of a previously published cross-sectional retrospective study. Nine of the 100 patients had died, three declined follow-up and one could not be traced. The remaining 87 patients (49 females, 38 males) completed the study proforma at a median follow-up interval of 65 months (range 39-90). An analysis of initial plasma viscosity compared with rates of progression of joint score was performed.
RESULTS: Eighteen patients changed subgroup; 11 had an increase in the number of joints involved, six a decrease, and one changed from an oligoarticular pattern to predominant spondylitis. Within the polyarticular group 37/51 patients had an increase in the number of joints involved. For the whole population, there were significant increases in the number of joints involved (median 6 vs 11, P < 0.001 Wilcoxon signed rank) and Health Assessment Questionnaire scores (median 0.375 vs 0.5, P < 0.001). The median rate of joint progression was 0.42 peripheral joints per year (range 0-7.2). However, the rate of peripheral joint involvement was highest in the first year of arthritis (median 4.0 joints/yr) as measured in 13 patients who had onset within 12 months of baseline assessment. There were no significant differences in skin and nail scores although nine more patients had developed nail disease. There was a significant correlation between the initial viscosity and rate of progression of joint damage (Spearman correlation, P < 0.011).
CONCLUSIONS: Peripheral joint disease is progressive in the majority of patients with PsA and reinforces the need for effective monitoring and treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730539     DOI: 10.1093/rheumatology/keg217

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  73 in total

1.  The burden of psoriatic arthritis: a literature review from a global health systems perspective.

Authors:  Seina Lee; Alan Mendelsohn; Evelyn Sarnes
Journal:  P T       Date:  2010-12

Review 2.  Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

Authors:  Dafna D Gladman; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

3.  Can we identify psoriatic arthritis early?

Authors:  Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

4.  Assessment and treatment of psoriatic spondylitis.

Authors:  Peter Nash
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

5.  The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis.

Authors:  Arthur Kavanaugh
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

6.  Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.

Authors:  Maria Sole Chimenti; Augusta Ortolan; Mariagrazia Lorenzin; Paola Triggianese; Marina Talamonti; Luisa Costa; Francesco Caso; Marta Favero; Miriam Teoli; Marco Galluzzo; Raffaele Scarpa; Leonardo Punzi; Roberto Perricone; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

7.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

Authors:  Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  Arthritis Rheum       Date:  2009-02-15

8.  [Screening and early diagnosis of psoriasis arthritis].

Authors:  P Härle
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

Review 9.  Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.

Authors:  Ennio Lubrano; Fabio Massimo Perrotta
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

10.  Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.

Authors:  Patrick Lee Dominguez; M Elaine Husni; Elizabeth W Holt; Stephanie Tyler; Abrar A Qureshi
Journal:  Arch Dermatol Res       Date:  2009-07-15       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.